GlassScriptPhysician profile
Charles P Coyne
NPI 1295048031
$6,194.85
in general payments reported to CMS, 2019-2025
37 companies · $770 in 2025
The $770 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $589 · 2021: $1,304 · 2022: $1,227 · 2023: $974 · 2024: $1,227 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,970.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $975.07 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $925.35 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $829.19 | 2019-2025 | Mounjaro, Emgality, Reyvow |
| Novo Nordisk INC | $411.88 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.55 | 2020-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $309.64 | 2020-2025 | Austedo Xr, Austedo, Ajovy |
| Amgen INC. | $264.56 | 2020-2025 | Evenity, Prolia, Prolia |
| Merck Sharp & Dohme LLC | $246.38 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $218.50 | 2020-2025 | |
| Organon LLC | $173.04 | 2024-2025 | Nexplanon |
| Glaxosmithkline, LLC. | $160.70 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $144.49 | 2020-2022 | |
| Astellas Pharma US INC | $129.29 | 2021-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.04 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $112.51 | 2020-2025 | Rexulti |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Coyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.